Compass Therapeutics Investor Presentation Deck

Phase 2 CTX-009 Combination Study (S. Korea) Patients with biliary tract cancers after one or two prior therapies Simon 2 Stage adaptive design COMPASS THERAPEUTICS Stage 1 CTX-009 at 10 mg/kg biweekly Paclitaxel 80 mg/m² weekly 3 of 4 weeks N = 21 3 or more PRs Stage 2 CTX-009 at 10 mg/kg biweekly Paclitaxel 80 mg/m² weekly 3 of 4 weeks N = 45 additional patients 15

View entire presentation